TAK 603

Drug Profile

TAK 603

Latest Information Update: 13 Feb 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Takeda
  • Developer Abbott Laboratories; Takeda; TAP Pharmaceutical Products
  • Class Anti-inflammatories; Disease-modifying antirheumatics; Osteoporosis therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Crohn's disease; Postmenopausal osteoporosis; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 02 Oct 2001 No-Development-Reported for Crohn's disease in USA (Unknown route)
  • 02 Oct 2001 No-Development-Reported for Psoriasis in USA (Unknown route)
  • 02 Oct 2001 No-Development-Reported for Rheumatoid arthritis in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top